标题：重组人白细胞介素-11预防急性白血病化疗后血小板减少疗效观察

      作者：唐春娟 1，侯蕊 2，李禹兵 2    宝鸡市人民医院药剂科 1、血液肿瘤科 2，陕西 宝鸡 721000

      卷次： 2019年30卷2期

      【摘要】 目的 探讨重组人白细胞介素-11 (rhIL-11)预防急性白血病化疗后血小板减少的临床效果。方法 选择2016年5月至2017年5月宝鸡市人民医院收治的急性白血病患者共56例，按照随机数表法分为观察组和对照组，每组28例。对照组采用常规化疗，观察组在此基础上采用 rhIL-11治疗，治疗时间28 d。治疗后比较两组患者的血小板计数最低值、血小板恢复至100×109/L的时间、平均血小板输注量、出血情况和不良反应发生率。结果 观察组和对照组血小板最低值[(8.5±1.6)×109/L vs (8.4±1.9)×109/L]比较，差异无统计学意义(P>0.05)；观察组患者血小板最高值为(167.4±25.3)×109/L，明显高于对照组的(91.8±20.6)×109/L，差异有统计学意义(P<0.05)；观察组患者的血小板恢复时间为(12.1±5.4) d，明显短于对照组的(16.7±6.1) d，差异有统计学意义(P<0.05)；观察组患者血小板输注量为(7.0±3.5) U，明显低于对照组 (10.4±3.9) U，差异有统计学意义(P<0.05)；观察组患者中有6例(21.4%)出现出血状况，包括3例皮肤瘀点瘀斑，2例黏膜出血和1例内脏出血，对照组有17例(60.7%)出现出血状况，包括9例皮肤瘀点瘀斑，6例黏膜出血和2例内脏出血，两组比较差异有统计学意义(P<0.05)。结论 rhIL-11预防急性白血病化疗后血小板减少效果确切，可以有效促进血小板生成，值得临床推广应用。
      【关键词】 重组人白细胞介素-11；急性白血病；化疗；血小板减少；疗效
      【中图分类号】 R733.71 【文献标识码】 A 【文章编号】 1003—6350（2019）02—169—03T

herapeutic effect of recombinant human interleukin-11 on prevention of thrombocytopenia after chemotherapyin acute leukemia.
TANG Chun-juan 1, HOU Rui 2, LI Yu-bing 2. Department of Pharmacy 1, Department of Hematologyand Oncology 2, Baoji People's Hospital, Baoji 721000, Shaanxi, CHINA
【Abstract】 Objective To investigate the clinical effect of recombinant human interleukin-11 (rhIL-11) in pre-venting thrombocytopenia after chemotherapy in acute leukemia. Methods A total of 56 patients with acute leukemiaadmitted to Baoji People's Hospital from May 2016 to May 2017 were randomly divided into an observation group and acontrol group according to the random number table method, with 28 cases in each group. The control group receivedconventional chemotherapy, and the observation group was treated with irhIL-11 on the basis of the control group; thetreatment time was 28 days. After treatment, the lowest platelet counts, the time of platelet recovery to 100×109/L, mean plate-let transfusion volume, bleeding, and adverse reaction rates were compared between the two groups. Results There was nosignificant difference in the lowest platelet count between the observation group and the control group: (8.5±1.6)×109/Lvs (8.4±1.9)×109/L, P>0.05. The highest platelet value in the observation group was (167.4±25.3)×109/L, which was sig-nificantly higher than (91.8±20.6)×109/L in the control group (P>0.05). The platelet recovery time in the observationgroup was significantly shorter than that in the control group: (12.1±5.4) d vs (16.7±6.1) d, P<0.05. The platelet transfu-sion volume of the observation group was significantly lower than that of the control group: (7.0±3.5) U vs (10.4±3.9) U,P<0.05. Bleeding occurred in 6 patients (21.4%) in the observation group, including 3 cases of skin ecchymosis, 2 casesof mucosal hemorrhage and 1 case of visceral hemorrhage. In the control group, 17 cases (60.7%) showed bleeding, in-cluding 9 cases of skin petechia, 6 cases of mucosal hemorrhage and 2 cases of visceral hemorrhage; all differences be-tween the two groups were statistically significant (P<0.05). Conclusion Recombinant human interleukin-11 can pre-vent thrombocytopenia after chemotherapy in acute leukemia, and can effectively promote platelet production, which isworthy of clinical application.
      【Key words】 Human recombinant interleukin-11; Acute leukemia; Chemotherapy; Thrombocytopenia; Thera-peutic effect